Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

PURPOSE: Ibrutinib has shown activity in non–germinal center B-cell diffuse large B-cell lymphoma (DLBCL). This double-blind phase III study evaluated ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in untreated non–germinal center B-cell DLBCL. PATIE...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Oncol
Egile Nagusiak: Younes, Anas, Sehn, Laurie H., Johnson, Peter, Zinzani, Pier Luigi, Hong, Xiaonan, Zhu, Jun, Patti, Caterina, Belada, David, Samoilova, Olga, Suh, Cheolwon, Leppä, Sirpa, Rai, Shinya, Turgut, Mehmet, Jurczak, Wojciech, Cheung, Matthew C., Gurion, Ronit, Yeh, Su-Peng, Lopez-Hernandez, Andres, Dührsen, Ulrich, Thieblemont, Catherine, Chiattone, Carlos Sergio, Balasubramanian, Sriram, Carey, Jodi, Liu, Grace, Shreeve, S. Martin, Sun, Steven, Zhuang, Sen Hong, Vermeulen, Jessica, Staudt, Louis M., Wilson, Wyndham
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2019
Gaiak:
ORIGINAL REPORTS
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6553835/
https://ncbi.nlm.nih.gov/pubmed/30901302
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.02403
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak